<DOC>
	<DOCNO>NCT01014793</DOCNO>
	<brief_summary>In acromegaly , nearly 40 % patient fail control GH/IGF-I level somatostatin analogue ( SA ) . Dopaminergic agonist ( DA ) even less effective , combination therapy SA DA normalize IGF-I level 33-56 % patient short-term study . This study design evaluate short long term efficacy cabergoline control IGF-I level acromegalic patient receive octreotide .</brief_summary>
	<brief_title>Short Long Term Efficacy Combined Cabergoline Octreotide Treatment Acromegalic Patients</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<mesh_term>Cabergoline</mesh_term>
	<criteria>Active disease , octreotide treatment least 9 month Cabergoline allergy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Acromegaly resistant</keyword>
	<keyword>combined-treatment</keyword>
	<keyword>dopamine agonist</keyword>
</DOC>